Agenus' bot/bal selected for two presentations at upcoming aacr io annual meeting

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today announced that bot/bal will be featured in two presentations at the upcoming american association for cancer research (aacr) io annual meeting that will take place on february 23-26 in los angeles, california. an oral presentation will highlight interim data from the ongoing phase 2 study of botensilimab and balstilimab (bot/bal) in combination with mink therapeutics' inkt cell therapy, agent-797,.
AGEN Ratings Summary
AGEN Quant Ranking